Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

17.23USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$17.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
97,786
52-wk High
$35.03
52-wk Low
$16.78

Latest Key Developments (Source: Significant Developments)

Revance Announces Pricing Of Public Offering Of Common Stock
Thursday, 17 Jan 2019 06:50am EST 

Jan 17 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.88 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.  Full Article

Revance Announces Proposed Public Offering Of Common Stock
Tuesday, 15 Jan 2019 04:17pm EST 

Jan 15 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS - PROPOSED PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL ABOUT $100 MILLION OF SHARES OF COMMON STOCK.  Full Article

Revance Announces China Market License Agreement With Fosun Pharma For RT002
Tuesday, 4 Dec 2018 08:06am EST 

Dec 4 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES CHINA MARKET LICENSE AGREEMENT WITH FOSUN PHARMA FOR RT002.REVANCE THERAPEUTICS INC - UPFRONT PAYMENT OF $30 MILLION, PLUS POTENTIAL MILESTONE PAYMENT AND TIERED ROYALTIES ON FUTURE SALES.REVANCE THERAPEUTICS INC - REVANCE ELIGIBLE TO RECEIVE ADDITIONAL POTENTIAL DEVELOPMENT AND SALES MILESTONE PAYMENTS OF UP TO $230.5 MILLION.REVANCE THERAPEUTICS INC - NO TRANSFER OF INTELLECTUAL PROPERTY..REVANCE THERAPEUTICS INC - REVANCE ELIGIBLE TO RECEIVE TIERED LOW-DOUBLE-DIGIT TO HIGH-TEEN ROYALTY PAYMENTS ON FUTURE NET SALES FROM DEAL.REVANCE THERAPEUTICS INC - FOSUN PHARMA WILL BE RESPONSIBLE FOR CONDUCTING NECESSARY CLINICAL STUDIES, MARKETING AND SALES IN TERRITORY.REVANCE THERAPEUTICS - FOSUN HAS EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE DAXIBOTULINUMTOXINA FOR INJECTION IN MAINLAND CHINA, HONG KONG AND MACAU.  Full Article

Revance Releases Second Quarter 2018 Results
Thursday, 2 Aug 2018 04:05pm EDT 

Aug 2 (Reuters) - Revance Therapeutics Inc ::REVANCE RELEASES SECOND QUARTER 2018 RESULTS.REVANCE THERAPEUTICS - EXPECTS TO COMPLETE SAKURA 3 OPEN-LABEL, LONG-TERM SAFETY STUDY OF RT002 FOR TREATMENT OF GLABELLAR (FROWN) LINES IN Q4.REVANCE THERAPEUTICS - ON TRACK TO FILE BLA FOR RT002 TO TREAT GLABELLAR (FROWN) LINES IN H1 2019.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2018 WERE $233.7 MILLION.REVANCE THERAPEUTICS - REITERATES FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018.Q2 REVENUE $0.7 MILLION VERSUS $0.1 MILLION.REVANCE THERAPEUTICS QTRLY DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.94.Q2 EARNINGS PER SHARE VIEW $-0.94, REVENUE VIEW $514000.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Revance Says Lauren Silvernail Has Resigned As Co's Chief Financial Officer
Tuesday, 29 May 2018 07:00am EDT 

May 29 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.REVANCE THERAPEUTICS INC -LAUREN SILVERNAIL HAS RESIGNED AS REVANCE'S CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER, EFFECTIVE AS OF MAY 29, 2018.REVANCE THERAPEUTICS INC - REVANCE IS INITIATING A SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.  Full Article

Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS.REVANCE THERAPEUTICS INC - TRIAL'S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002.REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8.REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002'S ABILITY TO TREAT PLANTAR FASCIITIS.  Full Article

Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018
Thursday, 4 Jan 2018 08:30am EST 

Jan 4 (Reuters) - Revance Therapeutics Inc ::REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018.REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018.REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION.REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION.  Full Article

Revance Announces Pricing Of Public Offering Of Common Stock
Thursday, 7 Dec 2017 08:30am EST 

Dec 7 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $31.00 PER SHARE​.  Full Article

Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​
Tuesday, 5 Dec 2017 05:20pm EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​.  Full Article

Revance Announces Proposed Public Offering Of Common Stock
Tuesday, 5 Dec 2017 04:45pm EST 

Dec 5 (Reuters) - Revance Therapeutics Inc ::REVANCE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK.REVANCE THERAPEUTICS INC - CERTAIN STOCKHOLDERS OF CO ARE ALSO OFFERING 600,000 SHARES OF COMPANY'S COMMON STOCK FOR SALE TO PUBLIC.  Full Article

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.